Health Economics›Bladder cancer›Locally advanced or metastatic disease, refractory/intolerant to platinum chemotherapy

Locally advanced or metastatic disease, refractory/intolerant to platinum chemotherapy

Bladder cancer · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	10.0 mo	52	R 14 921 674 PFS proxy	1
Enfortumab vedotin and Pembrolizumab Variant #01 Partial	—	R 81 987	21d	~12.5 mo	~32.7 mo	~36	~R 2 869 553 PFS proxy · indirect	4
Docetaxel and Ramucirumab Variant #01	—	R 62 164	21d	4.8 mo	—	2	R 124 328 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	~5.5 mo	~16.2 mo	~2	~R 32 087 PFS proxy · indirect	17
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	~3.0 mo	~9.0 mo	~4	~R 52 900 PFS proxy · indirect	21
MVAC Variant #02	—	R 5 442	28d	—	~15.3 mo	~2	~R 10 883 PFS proxy · indirect	4
Gemcitabine and Paclitaxel Variant #01	—	R 5 224	21d	—	7.8 mo	6	R 31 344 PFS proxy	—
Docetaxel monotherapy Variant #02	—	R 2 921	28d	2.8 mo	8.9 mo	8	R 23 372 PFS proxy	6
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	—	—	~7	~R 11 705 PFS proxy · indirect	1
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	8.9 mo	7	R 5 141 PFS proxy	4
Avelumab monotherapy Variant #01 Partial	—	—	14d	—	~22.6 mo	~2	—	2
Erdafitinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Toripalimab monotherapy Variant #01 Partial	—	—	14d	—	—	~11	—	—
Vinflunine monotherapy Variant #01 Partial	—	—	21d	—	8.0 mo	2	—	4
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	~16.0 mo	~2	—	3
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	~72.3 mo	~2	—	2

16 of 16 regimens shown